Dennis Liotta

Dr. Dennis Liotta

Emory University, Atlanta GA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

28 February 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CACourtney Aldrich
Courtney Aldrich
CBCarolyn Bertozzi
Carolyn Bertozzi
GGGunda I Georg
Gunda I Georg
LKLaura Kiessling
Laura Kiessling
CLCraig Lindsley
Craig Lindsley
SWShaomeng Wang
Shaomeng Wang

26 September 2012 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
RSRose M Santangelo
Rose M Santangelo
TATimothy M Acker
Timothy M Acker
SZSommer S Zimmerman
Sommer S Zimmerman
BKBrooke M Katzman
Brooke M Katzman
KSKatie L Strong
Katie L Strong
Dennis LiottaDennis Liotta
Dennis Liotta
Introduction: The NMDA receptor is a ligand-gated ion channel that plays a critical role in higher level brain processes and has been implicated in a range of neurological and psychiatric condition...

2 November 2017 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
SSSharon Swanger
Sharon Swanger
KVKatie M. Vance
Katie M. Vance
TATimothy M. Acker
Timothy M. Acker
SZSommer S. Zimmerman
Sommer S. Zimmerman
JDJohn O. DiRaddo
John O. DiRaddo
STStephen F. Traynelis
Stephen F. Traynelis

2 April 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZLZhongxing Liang
Zhongxing Liang
WZWeiqiang Zhan
Weiqiang Zhan
AZAizhi Zhu
Aizhi Zhu
YYYounghyoun Yoon
Younghyoun Yoon
SLSongbai Lin
Songbai Lin
HSHyunsuk Shim
Hyunsuk Shim
Metastasis, the spread and growth of tumor cells to distant organ sites, represents the most devastating attribute and plays a major role in the morbidity and mortality of cancer. Inflammation is crucial for malignant tumor transformation and survival. Thus, blocking inflammation is expected to serve as an effective cancer treatment. Among anti-inflammation therapies, chemokine modulation is now beginning to emerge from the pipeline. CXC chemokine receptor-4 (CXCR4) and its ligand stromal cell-derived factor-1 (CXCL12) interaction and the resulting cell signaling cascade have emerged as highly relevant targets since they play pleiotropic roles in metastatic progression. The unique function of CXCR4 is to promote the homing of tumor cells to their microenvironment at the distant organ sites. We describe the actions of N,N′-(1,4-phenylenebis(methylene))dipyrimidin-2-amine (designated MSX-122), a novel small molecule and partial CXCR4 antagonist with properties quite unlike that of any other reported CXCR4 antagonists, which was prepared in a single chemical step using a reductive amination reaction. Its specificity toward CXCR4 was tested in a binding affinity assay and a ligand competition assay using 18F-labeled MSX-122. The potency of the compound was determined in two functional assays, Matrigel invasion assay and cAMP modulation. The therapeutic potential of MSX-122 was evaluated in three different murine models for inflammation including an experimental colitis, carrageenan induced paw edema, and bleomycin induced lung fibrosis and three different animal models for metastasis including breast cancer micrometastasis in lung, head and neck cancer metastasis in lung, and uveal melanoma micrometastasis in liver in which CXCR4 was reported to play crucial roles. We developed a novel small molecule, MSX-122, that is a partial CXCR4 antagonist without mobilizing stem cells, which can be safer for long-term blockade of metastasis than other reported CXCR4 antagonists.

28 February 2017 in ACS Central Science
Verified
Journal Article
Open access
CACourtney Aldrich
Courtney Aldrich
CBCarolyn Bertozzi
Carolyn Bertozzi
GGGunda I Georg
Gunda I Georg
LKLaura Kiessling
Laura Kiessling
CLCraig Lindsley
Craig Lindsley
SWShaomeng Wang
Shaomeng Wang